Stephen Salloway, MD, MS is Director of Neurology and the Memory and Aging Program at Butler Hospital in Providence, Rhode Island, and the Martin M. Zucker Professor of Psychiatry and Human Behavior and Professor of Neurology at the Warren Alpert Medical School of Brown University. His research focuses on biomarker and drug development for prevention and early treatment of Alzheimer’s disease. During his time at Brown, the Butler Hospital Memory and Aging Program (MAP) has become an internationally recognized center for clinical research in Alzheimer’s disease. The MAP has helped pioneer the use of PET ligands for amyloid and tau to study the evolution of Alzheimer’s disease pathophysiology in autosomal dominant and sporadic Alzheimer’s disease. The program has had a lead role in testing targeted treatments, such as BACE inhibitors and monoclonal antibodies, alone and in combination, to lower amyloid plaques and neurofibrillary tangles, as well as novel approaches, such as deep brain stimulation, to slow the progression of Alzheimer’s disease. The MAP is developing new strategies using genetic testing and brain imaging to recruit cognitively normal elderly at increased risk for Alzheimer’s disease for prevention studies.
Dr. Salloway has published more than 370 scientific articles and abstracts and has edited 3 books. These include lead authorship on pivotal trials in the New England Journal of Medicine, the Lancet, Nature, and JAMA Neurology. Dr. Salloway is a past president of the American Neuropsychiatric Association, a fellow of the American Academy of Neurology, and a member of the American Neurological Association. He serves on the Steering Committees for landmark NIH studies such as the Alzheimer’s Disease Neuroimaging Initiative, the Dominantly Inherited Alzheimer’s Network, and the Alzheimer’s Disease Clinical Trial Consortium. He is a scientific reviewer for the National Institutes of Health and for more than 30 journals, universities, and research foundations, and lectures widely on prevention and early intervention for Alzheimer’s disease. Dr. Salloway received his MD from Stanford Medical School and completed residencies in neurology and psychiatry at Yale University.